| Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP (NCT05308017) | Northwestern University | 2022-05-01 |
| Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP) (NCT05082142) | Northwestern University | 2021-09-17 |
| Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial (NCT04781049) | San Carlo di Nancy Hospital | 2021-01-01 |
| Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP (NCT04398420) | Olympus Surgical Technologies Europe | 2020-08-27 |
| Comparison of Different Energy Sources During TUR-P (NCT02533687) | Selcuk University | 2020-07-01 |
| Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones. (NCT03630926) | Intermountain Health Care, Inc. | 2018-10-16 |
| Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter (NCT03423979) | Urotronic Inc. | 2017-12-19 |
| Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH) (NCT02676544) | Rhode Island Hospital | 2015-12-01 |
| Safety and Efficacy of OCL 503 in Prostate Artery Embolization (NCT02509975) | IMBiotechnologies Ltd. | 2015-09-01 |
| Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours (NCT02401581) | Centre Hospitalier Universitaire de Nice | 2015-02-02 |
| Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study (NCT02051036) | JUNGNAM KWON | 2014-02-01 |
| Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate (NCT02429219) | University of Magdeburg | 2013-11-01 |
| The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly (NCT01342562) | Yonsei University | 2010-11-01 |
| Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH (NCT01260129) | JW Pharmaceutical | 2010-10-01 |
| Prostate Cancer Antigen 3 (PCA-3) Gene Project (NCT01177436) | Assistance Publique Hopitaux De Marseille | 2009-09-01 |
| Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia (NCT00771394) | Astellas Pharma Inc | 2008-10-01 |
| Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) (NCT00670306) | AEterna Zentaris | 2008-03-01 |
| Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) (NCT00663858) | AEterna Zentaris | 2008-03-01 |
| Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow (NCT00634608) | University of Missouri-Columbia | 2008-02-01 |
| Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) (NCT00449150) | AEterna Zentaris | 2007-03-01 |
| The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate (NCT00427219) | Spectrum Pharmaceuticals, Inc | 2007-01-23 |
| Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) (NCT00037141) | American Medical Systems | 2002-03-01 |
| Clinical Trial in Males With BPH (Enlarged Prostate) (NCT00029822) | Sanofi | 2001-05-01 |